Contemporary concepts of the rational use of centrally acting skeletal muscle relaxants in the treatment of vertebrogenic dorsalgia
- 30 December 2025
- journal article
- review article
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 154-160
Abstract
Centrally acting skeletal muscle relaxants (CMs) in combination with nonsteroidal anti-inflammatory drugs and vitamins B are among the most frequently prescribed medications for the treatment of dorsalgia. Despite belonging to the same clinical and pharmacological group, CMs differ from each other in both their mechanism of action and the range of adverse effects. The emergence of new CMs in clinical practice demonstrates the growing innovation of this class of pharmacological agents in the treatment of musculoskeletal pain, necessitating a detailed study of the competitive advantages of individual CMs to improve treatment efficacy and safety.Keywords
This publication has 26 references indexed in Scilit:
- Oral non-benzodiazepine muscle-relaxants for people with acute and chronic primary low back pain: a systematic review with meta-analysisEuropean Spine Journal, 2025
- Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overviewEuropean Spine Journal, 2018
- Time to recovery in patients with acute painful musculoskeletal conditions treated with extended-release or immediate-release cyclobenzaprineAdvances in Therapy, 2011
- Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trialAdvances in Therapy, 2009
- Open experience with a new myorelaxant agent for low back painAdvances in Therapy, 2008
- Cochrane Database of Systematic ReviewsCochrane Database of Systematic Reviews, 2007
- Cyclobenzaprine and Back PainArchives of internal medicine (1960), 2001
- Hallucinations in an Elderly Patient Taking Recommended Doses of CyclobenzaprineArchives of internal medicine (1960), 2000
- Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studiesJournal of Neural Transmission, 1995
- Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of FibromyalgiaArthritis & Rheumatism, 1994